HER2-targeted therapy has been proven to significantly improve the prognosis of patients with HER2-positive breast cancer [7], while the addition of trastuzumab to adjuvant chemotherapy did not improve the prognosis of patients with HER2-low breast cancer, as shown in NSABP B-47 [8]. Here, ERBB2 is linked to breast carcinoma.